Total Payments
$72,210
2024 Payments
$9,592
Companies
7
Transactions
79
Medicare Patients
1,908
Medicare Billing
$249,606
Payment Breakdown by Category
Consulting$40,925 (56.7%)
Other$27,075 (37.5%)
Food & Beverage$3,192 (4.4%)
Travel$1,018 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $40,925 | 11 | 56.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $27,075 | 11 | 37.5% |
| Food and Beverage | $3,192 | 54 | 4.4% |
| Travel and Lodging | $1,018 | 3 | 1.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $43,076 | 27 | $0 (2024) |
| ABBVIE INC. | $28,600 | 40 | $0 (2024) |
| Organogenesis Inc. | $220.60 | 5 | $0 (2022) |
| KCI USA, Inc. | $175.80 | 3 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $74.55 | 2 | $0 (2022) |
| Mindray DS USA, Inc. | $49.06 | 1 | $0 (2023) |
| CashFlow Solutions, LLC | $14.26 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,592 | 10 | ABBVIE INC. ($8,418) |
| 2023 | $49,123 | 48 | Aroa Biosurgery Incorporated ($31,291) |
| 2022 | $13,462 | 19 | Aroa Biosurgery Incorporated ($10,611) |
| 2020 | $32.70 | 2 | KCI USA, Inc. ($16.94) |
All Payment Transactions
79 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/13/2024 | Aroa Biosurgery Incorporated | — | Food and Beverage | Cash or cash equivalent | $62.42 | General |
| 05/29/2024 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,325.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/08/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $88.09 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/02/2024 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,375.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/06/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/27/2024 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,375.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/15/2024 | Aroa Biosurgery Incorporated | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 02/15/2024 | Aroa Biosurgery Incorporated | — | Food and Beverage | Cash or cash equivalent | $61.92 | General |
| 02/08/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/08/2024 | ABBVIE INC. | DALVANCE (Drug) | Travel and Lodging | In-kind items and services | $5.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/17/2023 | Aroa Biosurgery Incorporated | — | Consulting Fee | Cash or cash equivalent | $3,197.79 | General |
| 11/07/2023 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,375.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/02/2023 | Aroa Biosurgery Incorporated | — | Food and Beverage | Cash or cash equivalent | $68.24 | General |
| 10/26/2023 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $80.72 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/18/2023 | Aroa Biosurgery Incorporated | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 10/17/2023 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,375.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/12/2023 | Aroa Biosurgery Incorporated | — | Food and Beverage | Cash or cash equivalent | $69.25 | General |
| 10/11/2023 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,375.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/28/2023 | Aroa Biosurgery Incorporated | — | Food and Beverage | Cash or cash equivalent | $19.53 | General |
| 09/21/2023 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $39.39 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/14/2023 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $40.31 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/13/2023 | Aroa Biosurgery Incorporated | — | Consulting Fee | Cash or cash equivalent | $3,700.00 | General |
| 09/12/2023 | Aroa Biosurgery Incorporated | — | Food and Beverage | Cash or cash equivalent | $134.54 | General |
| 08/16/2023 | Aroa Biosurgery Incorporated | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 07/28/2023 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 600 | 1,212 | $769,886 | $103,194 |
| 2022 | 11 | 665 | 814 | $843,169 | $75,669 |
| 2021 | 6 | 466 | 485 | $693,118 | $53,011 |
| 2020 | 4 | 177 | 182 | $199,664 | $17,731 |
Total Patients
1,908
Total Services
2,693
Medicare Billing
$249,606
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 100 | 591 | $192,114 | $37,783 | 19.7% |
| 99285 | Emergency department visit with high level of medical decision making | Facility | 2023 | 131 | 131 | $222,502 | $19,054 | 8.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 102 | 126 | $89,802 | $17,556 | 19.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 55 | 55 | $116,970 | $9,735 | 8.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 14 | 67 | $35,182 | $6,916 | 19.7% |
| 99284 | Emergency department visit with moderate level of medical decision making | Facility | 2023 | 63 | 63 | $76,899 | $5,977 | 7.8% |
| 11042 | Removal of skin and tissue, 20.0 sq cm or less | Office | 2023 | 11 | 39 | $20,800 | $4,090 | 19.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 22 | 35 | $7,145 | $1,409 | 19.7% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 102 | 105 | $8,472 | $674.23 | 8.0% |
| 99285 | Emergency department visit for life threatening or functioning severity | Facility | 2022 | 227 | 231 | $474,418 | $37,568 | 7.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 60 | 61 | $154,263 | $12,071 | 7.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 30 | 104 | $30,368 | $6,067 | 20.0% |
| 99284 | Emergency department visit for problem of high severity | Facility | 2022 | 56 | 57 | $81,672 | $5,875 | 7.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 24 | 25 | $20,325 | $4,056 | 20.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 14 | 42 | $15,876 | $3,167 | 19.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 19 | 21 | $11,634 | $2,323 | 20.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 13 | 48 | $7,632 | $1,520 | 19.9% |
| 99283 | Emergency department visit for problem of moderate severity | Facility | 2022 | 26 | 26 | $22,352 | $1,367 | 6.1% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 183 | 186 | $17,484 | $1,237 | 7.1% |
| 99282 | Emergency department visit for problem of mild to moderate severity | Facility | 2022 | 13 | 13 | $7,145 | $417.89 | 5.8% |
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2021 | 203 | 215 | $440,534 | $34,856 | 7.9% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2021 | 100 | 102 | $145,704 | $10,206 | 7.0% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 17 | 18 | $45,674 | $3,965 | 8.7% |
| 99283 | Emergency department visit, moderately severe problem | Facility | 2021 | 51 | 51 | $44,162 | $2,895 | 6.6% |
| 99282 | Emergency department visit, low to moderately severe problem | Facility | 2021 | 18 | 18 | $9,430 | $581.20 | 6.2% |
About Dr. Basil Khalaf, M.D
Dr. Basil Khalaf, M.D is a Undersea and Hyperbaric Medicine healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/13/2011. The National Provider Identifier (NPI) number assigned to this provider is 1285924142.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Basil Khalaf, M.D has received a total of $72,210 in payments from pharmaceutical and medical device companies, with $9,592 received in 2024. These payments were reported across 79 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($40,925).
As a Medicare-enrolled provider, Khalaf has provided services to 1,908 Medicare beneficiaries, totaling 2,693 services with total Medicare billing of $249,606. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Undersea and Hyperbaric Medicine
- Other Specialties Emergency Medicine
- Location Houston, TX
- Active Since 04/13/2011
- Last Updated 11/23/2022
- Taxonomy Code 207PE0005X
- Entity Type Individual
- NPI Number 1285924142
Products in Payments
- DALVANCE (Drug) $28,595
- Puraply (Medical Supply) $220.60
- ACTIV.A.C. (Device) $83.32
- V.A.C. VERAFLO CLEANSE CHOICE (Device) $75.54
- ANDEXXA (Biological) $74.55
- TE7 MAX (Device) $49.06
- SNAP (Device) $16.94
- LYMPHA PRESS OPTIMAL PLUS(US) BT (Device) $14.26
- TEFLARO (Drug) $4.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.